(Q33509626)

27 July 2017

1 reference

17 September 2019

1 reference

systematic review

1 reference

title

Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology (English)

1 reference

27 July 2017

1 reference

17 September 2019

1 reference

17 September 2019

1 reference

Norberto Carlos Chávez-Tapia

author

1

object named as

Norberto C Chavez-Tapia

0 references

Giorgio Bedogni

object named as

Giorgio Bedogni

3

0 references

Claudio Tiribelli

object named as

Claudio Tiribelli

6

0 references

Lory S Crocé

1 reference

ORCID Public Data File 2021

author name string

Felix I Tellez-Avila

2

1 reference

27 July 2017

Lory S Crocè

4

1 reference

27 July 2017

Flora Masutti

5

1 reference

27 July 2017

language of work or name

1 reference

9 October 2009

3 references

27 July 2017

21 March 2019

17 September 2019

3 references

27 July 2017

21 March 2019

17 September 2019

9

1 reference

27 July 2017

page(s)

75

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

copyright license

2 references

21 March 2019

on focus list of Wikimedia project

17 September 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Current and emerging therapies in nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Rimonabant for overweight or obesity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Review article: the treatment of fatty liver disease associated with the metabolic syndrome.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Review article: the metabolic syndrome and non-alcoholic fatty liver disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Quantifying heterogeneity in a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Bias in meta-analysis detected by a simple, graphical test

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

The effect of obesity on disability vs mortality in older Americans

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Compliance with physical activity recommendations in US adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Liver and heart: a new link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-9-75

Clinical update on non-alcoholic fatty liver disease and steatohepatitis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763866

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19818116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19818116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: Evidence for sex-specific differences

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19818116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-230X-9-75

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference